D
ietary sodium restriction is arguably the most frequent self-care behavior recommended to patients with heart failure (HF) 1, 2 and is endorsed by all HF guidelines. [2] [3] [4] [5] [6] [7] [8] [9] [10] However, the data on which this recommendation is drawn are modest, and the limited trials conducted have produced inconsistent findings. Americans consume Ϸ3700 mg sodium daily, 11 whereas the US Department of Agriculture and the Department of Health and Human Services recommend 2300 mg daily intake for the general population, with a stricter recommendation of 1500 mg/d for those Ͼ50 years of age, blacks, or individuals with hypertension, diabetes mellitus, or chronic kidney disease. 12 According to a recent report from the National Health and Nutrition Examination Survey, although 47 .6% of persons aged Ն2 years meet the criteria to limit daily sodium intake to 1500 mg, the usual intake for 98.6% of those persons was Ͼ1500 mg; in 88.2% of the remaining population, daily intake was greater than the recommended Ͻ2300 mg. 13 The American Heart Association now recommends sodium intake of 1500 mg/d for all Americans, 14 similar to the recommendation by the Institute of Medicine. 15 Interestingly, and paradoxically, the suggested 1500 mg daily sodium intake for the general population is less than the limit proposed for HF patients by most guidelines, which appears as a contradiction. Whether this contradiction suggests inconsistent policy or a limited understanding of sodium homeostasis in the HF versus non-HF state is debatable. Sodium homeostasis physiology is altered in HF as opposed to healthy individuals and those with hypertension, and may partially explain these incongruous recommendations. This review summarizes the studies assessing the effects of sodium restriction in HF, highlighting knowledge gaps and future directions.
Sodium Intake Recommendations and Patterns
Excessive sodium intake is associated with fluid retention. Therefore, all HF management guidelines recommend sodium restriction. In 2005, the American College of Cardiology and the American Heart Association HF guidelines recommended 3000 to 4000 mg daily sodium intake, 16 and, for patients with volume overload, restriction to 2000 mg/d. This recommendation was subsequently updated to moderate sodium restriction. 2 The Heart Failure Society of America recommends 2000 to 3000 mg daily sodium intake 17 and Ͻ2000 mg for patients with moderate to severe HF symptoms. The Table summarizes the most current recommendations by multiple organizations. Expert opinion and level of evidence C has been largely the basis for these recommendations. The inconsistency of guidelines underlines the weak database that supports this cornerstone treatment for such a serious condition. Data on sodium consumption among HF patients indicate limited compliance with recommended sodium restriction. In a recent study, when instructed to limit sodium intake to 2000 mg/d, HF patients averaged a daily intake of 2671 mg/d with a wide range, spanning between 522 and 9251 mg/d. 18 In another study, the reported sodium intake among HF patients was 3190 mg/d. 19 Sodium reduction is difficult to adhere to even among patients with symptomatic HF, with an estimated compliance rate of only 33% as noted by 3-day food diaries. 18 Congruent with this observation, a recent study reported that only 34% of patients consume Ͻ3000 mg and only 15% consume Ͻ2000 mg sodium daily based on their 24-hour urinary sodium excretion. 20 Sodium consumption Ͻ2000 mg/d is difficult to achieve even with dietician education, 21 and studies have demonstrated that sex 22 and race 23 affect dietary preferences and adherence to sodium restriction recommendations in patients with HF.
Sodium Homeostasis in HF
Heart failure may be associated with reduced cardiac output, elevated systemic venous pressures, or shunting of blood away from the kidneys; all may lead to diminished renal perfusion, in turn, activating the sympathetic nervous system 24 and the renin angiotensin aldosterone system, 25 and creating a vicious cycle of sodium and water retention despite fluid overload (Figure) . 25 Moreover, considering the hypoosmolar, volume-overloaded state, inappropriate physiological vasopressin levels are seen in HF. The natriuretic peptide system in HF is inadequate to counteract this dynamic because of decreased efficacy and inadequate cleaving of natriuretic peptides, 26, 27 downregulation of renal natriuretic peptide receptors, 28 and degradation of natriuretic peptides by endopeptidases in the renal tubule. 28 Therefore, despite the need for sodium and water excretion, sodium-retaining factors prevail. 29 Dietary sodium restriction is associated with further neurohormonal activation in HF. In animal studies, a sodiumrestricted diet leads to a decrease in cardiac output and increased vascular resistance owing to renin angiotensin aldosterone system activation. 30 Also, although blocking renin angiotensin aldosterone system does provide an improvement in renal blood flow, it is not associated with an increase in glomerular filtration rate or natriuresis when accompanied by a low-sodium diet. 30 Recently, the Valsartan in Heart Failure Trial investigators reported that higher plasma renin activity (PRA) was a strong and independent predictor of mortality regardless of angiotensin-converting enzyme inhibitor or ␤-blocker treatment. 31 Of note, in the Heart Outcomes Prevention Evaluation trial, high PRA was also an independent predictor of mortality in high-risk patients with atherosclerosis or diabetes mellitus without HF, regardless of allocation to ramipril. 32 These data question the view that neurohormonal activation in HF has limited prognostic importance in the presence of neurohormonal blockade.
Overview of Sodium Intake Studies in HF
Several studies have investigated the effects of dietary sodium in patients with HF, albeit randomized evidence is limited. Few studies evaluated outcomes, and most investigated the physiological effects of varying sodium in the diet. Most studies focused on dietary sodium restriction primarily, whereas others had additional features such as fluid restriction, diuretic dosing, and use of parenteral saline. To facilitate this discussion, sodium intake is classified into "very low" (230 -800 mg/d), "low" (1610 mg/d to 2000 mg/d), and "moderate-to-high" (2300 -5750 mg/d) dietary intake. Comparing these studies is challenging because of the variation in sample size, study design, sodium intervention, sodium intake assessment, and baseline HF therapy among the studies (online-only Data Supplement Table I ).
Physiological and Neurohormonal Responses
Decreased pulmonary artery and capillary wedge pressures without change in cardiac index and systemic vascular resistance was observed by Cody and colleagues 33 in New York Heart Association (NYHA) class III to IV patients with a very low sodium diet, but Damgaard and colleagues 34 noted a decrease in cardiac index and stroke volume and an increase in pulmonary vascular resistance with a low-sodium diet in NYHA class II to III patients. Two studies by Volpe and colleagues 35, 36 concluded that moderate-to-high sodium intake had no hemodynamic effects on NYHA I to II patients Only consensus opinion of experts, case studies, or standard of care; FairϭBenefits exceed the harms but quality of evidence is not as strong; 1ϩ ϭ well-conducted meta-analysis, systemic reviews, or randomized controlled trials with low risk of bias. NYHA indicates New York Heart Association.
but predisposed patients to sodium retention. Natriuretic peptide levels were affected inconsistently among studies; levels did not change significantly with dietary sodium modification in 4 studies using very low to moderate dietary sodium restriction, 34,36 -38 decreased in 2 studies with a moderate-to-high sodium diet, 35, 39 and increased in 3 studies with a low-sodium diet. 40 -42 Levels of neurohormones, such as PRA, norepinephrine, angiotensin-II, and urinary aldosterone, increased with dietary sodium restriction regardless of degree of restriction. 33-36,40 -42 Interestingly, Nakasato and colleagues 37 showed a differential effect on PRA according to body mass index; only in patients with lower body mass index did PRA increase with a very low sodium diet in comparison with a moderate-to-high sodium diet.
Diuresis, Electrolyte, and Renal Responses
Licata and colleagues, 43 Parrinello and colleagues, 42 and Paterna and colleagues 40, 41, 44 performed a series of studies with varied fluid restriction, diuretic dosing, low versus moderate to high dietary sodium intake, and/or the use of hypertonic saline infusion. Patients who received hypertonic saline and a moderate-to-high sodium diet had more diuresis and natriuresis in comparison with those who were not treated with hypertonic saline and consumed a low-sodium diet. Regardless of use of hypertonic saline, these studies demonstrated that low dietary sodium intake was associated with a significant increase in blood urea nitrogen and creatinine, whereas moderate-to-high sodium intake was related to decreased creatinine and an insignificant increase in blood urea nitrogen. 40 -44 The highest daily diuresis was observed among those receiving 500 mg/d furosemide, 2760 mg/d sodium diet, and strict fluid restriction (1000 mL/d). Those receiving 2760 mg/d sodium and 1000 mL/d fluid restriction, irrespective of diuretic dose, had better natriuresis and showed only a modest increase in creatinine and stable blood urea nitrogen levels, whereas other groups showed more increases in both creatinine and blood urea nitrogen. 40 
Outcomes
Adverse event rates, defined as HF or non-HF readmission rates and mortality rates, were higher with low-sodium diets in several studies. 40 -44 Mortality rate was lower in the moderate-to-high sodium group in 3 studies in comparison with low-sodium diet. [41] [42] [43] In studies evaluating the effects of low and moderate-to-high dietary sodium intake with or without hypertonic saline infusion, patients on the low- Effects of sodium intake in heart failure: low-sodium intake may have varied effect on heart failure. Intravascular volume contraction improves hemodynamics and reduces diuretic requirement, congestion, and myocardial wall stress, leading to compensated heart failure. Intravascular volume contraction, however, may also lead to a vicious cycle of increased sodium and water retention through neurohormonal activation predisposing to decompensated heart failure. AVP indicates arginine vasopressin; Na, sodium; K, potassium; MR, mitral regurgitation; PWCP, pulmonary wedge capillary pressure; red plus, diuretic action enhances contraction of intravascular volume; red minus, low diuretic doses reduce hormonal activation and contraction of intravascular volume. sodium diet without hypertonic saline infusion had longer hospital stays 43, 44 and higher readmission rates in comparison with those on the moderate-to-high sodium diet with hypertonic saline infusion; these differences were observed as early as 30 days and continued up to 12 months. 40 -42 Patients not randomly assigned because of inability to follow the prescribed fluid intake restriction, but still receiving the moderate-to-high sodium diet, had a higher rate of HF-related readmissions, similar to that observed in those receiving low-sodium diets, in comparison with those who were able to comply with fluid restriction. 41 Thus, restricted fluid intake may in part be responsible for these differences.
Two observational studies, however, showed different results. 20 , 45 Arcand and colleagues 45 showed that in a HF cohort consisting mostly of patients with NYHA class I to II symptoms, Ն2800 mg/d sodium resulted in more HF hospitalizations in comparison with those on lower intake. Lennie and colleagues 20 interestingly showed Ͻ3000 mg/d sodium was associated with better outcomes in NYHA class III to IV patients, whereas it was associated with significant increase in hospital visits, readmissions, and mortality in NYHA class I to II patients.
Critique
Clinical studies assessing the effect of sodium restriction on outcomes in HF are limited. Variances in protocols, fluid intake, actual measurement of sodium intake, and clinical and therapeutic characteristics among these studies make it challenging to compare data and draw definitive conclusions. Sodium intake is challenging to measure. Besides variable sodium intake among studies, another concern is that compliance with the prescribed sodium diets was not described in some studies or was subjectively assessed in others. Only in short-term studies in which the patients received a diet from a metabolic kitchen could sodium intake be strictly controlled. Concomitant fluid intake was described in some studies and it varied, whereas adherence to the recommended amount of fluid was either not reported or subjectively assessed. Earlier studies discontinued HF medications before randomization, 33, 35, 36 and later studies did not consistently have patients on optimal medical therapy. Hemodynamic changes varied in these studies in response to a restricted sodium diet; however, statistically significant adverse neurohormonal changes were consistently noted. The multiinterventional approach of several of these studies, eg, altering diuretic dose, fluid allowance, and sodium restriction, confounds the effect of sodium intake. 40 -42 With the exception of 1 observational study that evaluated patients with preserved ejection fraction, 36 all other studies focused on patients with HF and reduced ejection fraction. Thus, the physiological and clinical impact of dietary sodium restriction in HF with preserved ejection fraction is unknown. Finally, these data pertain almost exclusively to white patients. Considering the differences in neurohormonal activation, especially the renin angiotensin aldosterone system, and cardiovascular and renal pathophysiology among the races, especially blacks, the effects of sodium restriction in nonwhite HF patients cannot be ascertained from these studies.
Some studies have shown poor caloric intake and decreased nutritional status in patients who comply with sodium restriction, 18 ,46 -48 which may also impact HF outcomes. Whether dietary sodium intake in HF should be individualized, based on body weight, symptoms, renal function, or other characteristics, is uncertain.
These inconsistencies are in part related to studies with small sample sizes and conclusions based on nonrandomized data. Interestingly, the 3 larger randomized, controlled trials that assessed clinical outcomes showed congruent results, 40 -42 ie, lower sodium intake was associated with worse outcomes, including significantly higher mortality and readmission rates. However, all 3 of these studies were performed by the same group of investigators in a restricted geographic location enrolling postdischarge patients, and these effects were not independently confirmed by other investigators. In addition, in the largest of these studies, 40 multiple groups were tested for sodium effects, increasing the potential for type I error, and therefore the results need to be interpreted with caution. Finally, clinical evidence suggests that sodium restriction is associated with neurohormonal activation in HF, which may not be an innocent phenomenon even among treated patients. However, no study to date has evaluated the effects of sodium restriction on neurohormonal activation and outcomes in optimally treated HF patients. Although a significant proportion of patients in these studies were on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, few were on ␤-blockers or aldosterone antagonists. These data underscore the need for more definitive trials to assess the efficacy and safety of dietary sodium restriction in HF.
Conclusions
It is widely perceived that HF management should include dietary sodium restriction, a recommendation endorsed by all national and international guidelines. Given the generally accepted notion that increased sodium intake leads to increased fluid retention in HF, it has been assumed that a low-sodium diet as suggested for the general population would improve outcomes in HF patients also. Indeed, there are no conclusive data suggesting that the sodium intake recommended for the general population is unsafe for HF patients in the current era of medical therapy. Also, although adverse neurohormonal activation related to sodium restriction in HF remains a concern, its clinical relevance in an optimally treated patient is not known.
Currently, there are insufficient data to endorse any specific level of sodium intake with certainty, and differences among the various HF subpopulations are not known. Effects of sodium restriction in nonwhite HF patients and those with preserved ejection fraction are virtually unknown. The new American Heart Association recommendations for 1500 mg/d sodium appears to be appropriately applicable for patients with stage A and B HF, because of the data linking sodium intake with blood pressure, 49 incidence of hypertension, 50 left ventricular hypertrophy, 51 cardiovascular disease, 52 other HF risk factors, 52, 53 and even with incident HF per se. 54 However, it becomes evident from this review that for stage C and D HF patients, there are insufficient data to support a definitive recommendation. Physicians should consider some degree of sodium restriction in patients with stage C and D HF, but more data are needed to support a specific sodium intake level. The generation of guideline statements to support a fundamental recommendation such as dietary modifications in HF must not be relegated to consensus alone, but should be as evidence driven as drug and device therapy. The lack of a well-informed database puts patients with HF at risk for errant recommendations. We believe that there is a critical need for rigorously designed mechanistic, behavioral, and outcome trials to better study sodium homeostasis in HF and inform management of dietary intake of sodium in all severities of HF. This is especially true considering the signal for worse HF outcomes with sodium restriction in several studies. 46, 51, 52 We do know that very high sodium intake is not optimal, but we do not know (1) what the lower safest and most efficacious range is and (2) if that range would be applicable to all patients, or needs to be individualized. Thus, more "dose-ranging" sodium intake studies would be informative. At the minimum, a randomized clinical trial in patients with systolic HF should be considered that assess the effects of sodium restriction on clinical outcomes including mortality and hospitalization risk. Several different strategies are possible, one of which would be to randomly assign patients to moderate sodium restriction, ie, 2300 mg/d per the current recommendation, and 1500 mg/d, the strict recommendation for the general population proposed by the American Heart Association. However, these values are suggested more out of the concern to be consistent, if possible, with the national guidelines for the population at large. Importantly, these patients should undergo uniform fluid restriction according to current recommendations and be on optimal medical therapy when studying the effects of sodium intake.
Mechanistic studies can focus on effect of sodium restriction on the myocyte (both at the level of cellular signaling and also at the organ level), vasculature, renal function, and neurohormonal activation. However, these 4 physiological domains are directly affected by, or the effect of sodium on them can be modified by, baseline medical therapy. Thus, fundamental research with animal models and human studies on baseline standard therapy are likely to yield important insights. Moreover, mechanistic studies assessing the physiological effects and safety of dietary sodium restriction in patients with HF with preserved ejection fraction should also be conducted to inform larger outcome studies. It is also possible that the effect of sodium intake varies considerably among different individuals. Some ways to personalize sodium intake recommendations that could be assessed include studies based on genomic factors, body size, renal function, comorbidity burden, symptoms status, etc.
Beyond the mechanistic and clinical outcomes studies, further behavioral research is important. Heart failure patients, like the population at large, despite medical advice, continue to consume large quantities of sodium daily. Further research investigating reliable means of longer-term sodium intake assessment over time is important, because current means are either prone to recall bias (eg, food frequency questionnaires) or are episodic and reveal the status for the past 24 hours, which may not be reflective of the overall sodium intake pattern (eg, 24-hour urinary sodium measurements). How to best implement sodium intake recommendations so that the adherence rates improve, and how much that will involve advocacy versus behavior change interventions, needs further exploration. Alternate food-seasoning options that can satisfy taste preferences, but do not contain elements that in excess can be detrimental (eg, potassium content in individuals on angiotensin-converting enzyme inhibitor and aldosterone antagonists therapy), should be sought.
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